6 research outputs found

    OpusCleaner and OpusTrainer, open source toolkits for training Machine Translation and Large language models

    Full text link
    Developing high quality machine translation systems is a labour intensive, challenging and confusing process for newcomers to the field. We present a pair of tools OpusCleaner and OpusTrainer that aim to simplify the process, reduce the amount of work and lower the entry barrier for newcomers. OpusCleaner is a data downloading, cleaning, and proprocessing toolkit. It is designed to allow researchers to quickly download, visualise and preprocess bilingual (or monolingual) data that comes from many different sources, each of them with different quality, issues, and unique filtering/preprocessing requirements. OpusTrainer is a data scheduling and data augmenting tool aimed at building large scale, robust machine translation systems and large language models. It features deterministic data mixing from many different sources, on-the-fly data augmentation and more. Using these tools, we showcase how we can use it to create high quality machine translation model robust to noisy user input; multilingual models and terminology aware models.Comment: Code on Github: https://github.com/hplt-project/OpusCleaner and https://github.com/hplt-project/OpusTraine

    Unusual magnetoelectric effect in paramagnetic rare-earth langasite

    Get PDF
    Violation of time reversal and spatial inversion symmetries has profound consequences for elementary particles and cosmology. Spontaneous breaking of these symmetries at phase transitions gives rise to unconventional physical phenomena in condensed matter systems, such as ferroelectricity induced by magnetic spirals, electromagnons, non-reciprocal propagation of light and spin waves, and the linear magnetoelectric (ME) effect - the electric polarization proportional to the applied magnetic field and the magnetization induced by the electric field. Here, we report the experimental study of the holmium-doped langasite, Hox_{x}La3−x_{3-x}Ga5_5SiO14_{14}, showing a puzzling combination of linear and highly non-linear ME responses in the disordered paramagnetic state: its electric polarization grows linearly with the magnetic field but oscillates many times upon rotation of the magnetic field vector. We propose a simple phenomenological Hamiltonian describing this unusual behavior and derive it microscopically using the coupling of magnetic multipoles of the rare-earth ions to the electric field.Comment: 8 pages, 3 figure

    Initial experience with CytoSorb therapy in patients receiving left ventricular assist devices

    No full text
    BACKGROUND: The use of left ventricular assist devices (LVAD) in patients with advance heart failure is still associated with an important risk of immune dysregulation and infections. The aim of this study was to determine whether extracorporeal blood purification using the CytoSorb device benefits patients after LVAD implantation in terms of complications and overall survival.MATERIALS AND METHODS: Between August 2010 and January 2020, 207 consecutive patients underwent LVAD implantation, of whom 72 underwent CytoSorb therapy and 135 did not. Overall survival, major adverse events, and laboratory parameters were compared between 112 propensity score-matched patients (CytoSorb: 72 patients; non-CytoSorb: 40 patients).RESULTS: WBC (p = .033), CRP (p = .001), and IL-6 (p &lt; .001), significantly increased with LVAD implantation, while CytoSorb did not influence this response. In-hospital mortality and overall survival during follow-up were similar with CytoSorb. However, patients treated with CytoSorb were more likely to develop respiratory failure (54.2% vs. 30.0%, p = .024), need mechanical ventilation for longer than 6 days post-implant (50.0% vs. 27.5%, p = .035), and require tracheostomy during hospitalization (31.9% vs. 12.5%, p = .040). No other significant differences were observed with regard to major adverse events during follow-up.CONCLUSIONS: Overall, our results showed that CytoSorb might not convey a significant morbidity or mortality benefit for patients undergoing LVAD implantation.</p
    corecore